September 25, 2001

Vaccine Cuts Meningitis C Cases in Britain

Those under age 20 benefit greatly

(HealthDay) -- A vaccine against meningitis C that was introduced in Great Britain in 1999 has cut the number of cases among British youngsters by 80 percent, reports the Australian Broadcasting Corp..

The number of cases of the potentially deadly brain disease fell from 700 in 1999 to 142 last year among those most vulnerable -- people under age 20, the report says. Britain was the first country in the world to use the vaccine.

Chiron Corp. of Emory, Calif., one of the companies that makes the vaccine, says it expects to sell $100 million worth of the vaccine for the campaign to eradicate meningitis C in Britain.

This fact sheet provides background on the disease and the vaccine.

Stan Simon

Consumer News

Vaccine Cuts Meningitis C Cases in Britain

Those under age 20 benefit greatly

AAP Provides Guidance for Follow-Up Care for Pediatric COVID-19

Exposure to Flu-Like Illness in Doctor's Office Ups Odds of Return Visit

For U.S. Teens, Most Adverse Events to COVID-19 Vaccine Nonserious

Indiana University COVID-19 Vaccine Mandate Upheld by Federal Appeals Court

NYC Becomes First to Require Vaccination Proof for Indoor Activities

INFOGRAPHIC: The Bigger the City, the Lower the Depression Rates?

AAP Provides Guidance for Follow-Up Care for Pediatric COVID-19

Exposure to Flu-Like Illness in Doctor's Office Ups Odds of Return Visit

For U.S. Teens, Most Adverse Events to COVID-19 Vaccine Nonserious

Indiana University COVID-19 Vaccine Mandate Upheld by Federal Appeals Court

NYC Becomes First to Require Vaccination Proof for Indoor Activities

Wellness A-Z

HealthDay

Consumer Health News

Professional News